Q32 Bio (QTTB) awards 10,826 stock options to director
Rhea-AI Filing Summary
Q32 Bio Inc. director Kathleen LaPorte received a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. This amendment corrects the previously reported grant size. The options vest in full on the earlier of June 12, 2027 or the next annual meeting of stockholders, subject to her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
LAPORTE KATHLEEN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 10,826 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (2)
- F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
- F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Stock options granted: 10,826 options
Exercise price: 12.6400 per share
Underlying common shares: 10,826 shares
+2 more
5 metrics
Stock options granted
10,826 options
Grant to director Kathleen LaPorte on June 12, 2026
Exercise price
12.6400 per share
Exercise price of the reported stock option grant
Underlying common shares
10,826 shares
Common stock underlying the granted options
Option expiration date
June 11, 2036
Expiration of director stock option grant
Latest vesting date
June 12, 2027
Options vest by this date or earlier at next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) reported for the grant"
exercise price financial
"conversion_or_exercise_price of $12.6400 per share for the options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"The shares underlying this option shall vest and become exercisable in full"
annual meeting of stockholders financial
"earlier of June 12, 2027 or the date of the Issuer's next annual meeting of stockholders"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Q32 Bio (QTTB) report in this Form 4/A?
Q32 Bio reported that director Kathleen LaPorte was granted 10,826 stock options on June 12, 2026. These options are a compensation-related award, not an open-market purchase, and give her the right to buy common shares at a fixed exercise price.
Why was this Form 4/A amendment filed for Q32 Bio (QTTB)?
The amendment was filed to correct the number of options awarded to Kathleen LaPorte on June 12, 2026. It states that an earlier Form 4 from June 16, 2026 reported an incorrect grant size and this filing updates the option count.
How many Q32 Bio (QTTB) options did Kathleen LaPorte receive and at what price?
Kathleen LaPorte received 10,826 stock options, each with an exercise price of $12.64 per share. The options are for Q32 Bio common stock and, once vested, allow her to purchase an equal number of shares at that price.
What is the vesting schedule for Kathleen LaPorte’s Q32 Bio (QTTB) options?
The options vest and become fully exercisable on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders. Vesting is conditioned on her continued service with the company through that vesting date.
When do Kathleen LaPorte’s Q32 Bio (QTTB) stock options expire?
The reported stock options expire on June 11, 2036. After that date, any unexercised options will lapse, meaning they can no longer be used to purchase Q32 Bio common shares at the fixed $12.64 exercise price.
Were Kathleen LaPorte’s Q32 Bio (QTTB) option grants under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is marked as not affirmed, and there is no footnote stating that the grant was made under a 10b5-1 trading plan. The transaction is characterized as a compensation-related option award.